The company used approximately $4.4M of cash in the quarter ended December 31, 2024. “I am pleased with our team’s execution as we delivered our seventh consecutive quarter of double-digit revenue growth,” said Masoud Toloue, president and CEO of Quanterix (QTRX). “Despite a difficult capital spending environment, Quanterix has shown operational resiliency, and we expect to continue to build on this performance, as we enter 2025 from a position of strength. I am also excited about our recently announced acquisition of Akoya Biosciences. We believe we can create tremendous value by driving new growth and applying the same robust execution to the combined company.”
Stay Ahead of the Market:
- Discover outperforming stocks and invest smarter with Top Smart Score Stocks
- Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTRX:
- Quanterix price target lowered to $11 from $15 at TD Cowen
- Quanterix Announces Merger with Akoya Biosciences
- Quanterix Merges with Akoya for Enhanced Biomarker Solutions
- Quanterix to acquire Akoya Biosciences in an all-stock transaction
- Down More Than 60%: Analysts Expect These 2 Beaten-Down Stocks to Rebound in 2025